The Phillips Group Oncology Communications
Narrative Nexus of Clinical Data and Real-Time Insights

The Phillips Group (TPG) is a specialist in oncology and hematology with over 25-year history of providing exceptional medical communications services to the oncology community. TPG integrates clinical trial data with real-time industry developments, crafting narratives that resonate with physicians, patients, caregivers, and regulatory bodies. At the core of TPG’s operations is a dedicated team of senior medical writers, each of whom brings extensive experience garnered over years of service.

Mark Phillips, president of TPG, encapsulates the company ethos succinctly, stating, “We are a boutique family-owned medical communications company specializing in oncology, hematology, with medical writing as the cornerstone of our operations.”

TPG’s team of medical writers is not only highly qualified, holding advanced medical degrees, many with experience in prominent cancer centers, but they are also dynamic contributors to the field. They actively participate in the American Medical Writing Association, holding professional certifications that underscore their expertise and commitment to the highest standards of medical communication.

Through newsletters and patient meetings, TPG does more than share information; it enhances the patient and caregiver experience by offering crucial support and education. A conscientious effort is made to consider the broader context, extending beyond achieving publication, including the evaluation of the potential impact of each manuscript once it is disseminated.

The goal is to meticulously craft a manuscript that maximizes positive outcomes for patients. Quality, care, and consistency are foundational principles guiding every endeavor.

Each project undertaken by TPG commences with thorough information gathering and extensive dialogues with clients and authors. This fact-finding stage is crucial for ensuring a comprehensive understanding of requirements and available data. Subsequently, TPG devises a strategic plan to effectively communicate these findings to the community, prioritizing impactful dissemination beyond regulatory obligations. This may entail presenting findings orally, followed by manuscript publication, and the creation of a plain language summary for patients. In addition, TPG organizes continuing medical education (CME) events, collaborating with large hospital systems like Northside Hospital and the University of Pittsburgh to provide this crucial information to the community.

TPG’s expertise in the field allows it to craft agendas and communicate effectively with physicians. From the initial stages of drug development to the final dissemination of information to caregivers, nurses, and patients, TPG remains intricately involved at every step, recognizing the profound impact each stage has on patient outcomes. Engaging directly with patients during meetings and hearing about their journeys provides invaluable insights. Its newsletters created for Northside serve as a tangible conduit for data dissemination to patients and healthcare providers. “We have dedicated full-time teams for CME, manuscript writing, project management, and abstract/poster development,” Phillips adds, highlighting TPG’s adaptability and commitment to tailoring services to meet the distinct needs of each client and project.

Early in Phillips’ career, TPG provided value-based pricing and exceptional work to a small pharmaceutical company developing RAD1901, ultimately contributing to the drug’s eventual approval as a first-in-class oral therapy. Throughout the project, Phillips worked closely alongside the client’s chief medical officer (CMO). Together, they developed a publication plan and executed the publications with a small, efficient team. Following its acquisition by a larger company, TPG’s extensive expertise prompted its continued involvement with the drug, maintaining a partnership with the acquiring company. The collaboration with the client was crucial in publishing the necessary information, leading to subsequent FDA and EU approvals.

TPG’s commitment to excellence is reflected in its remarkably low attrition rates, which not only strengthen its knowledge base but foster strong, enduring relationships with clients and healthcare providers. Over the years, the TPG has garnered a global reputation among top healthcare providers and oncologists, owing to its focus on oncology and hematology.

With a diverse client portfolio ranging from smaller biotechs to mid-sized and larger pharmaceutical companies, TPG possesses a nuanced understanding of upcoming innovations and products already in circulation. This breadth of experience positions TPG to provide a bespoke, white-glove service tailored to each client’s specific needs, ensuring maximum value and return on investment (ROI).

Beyond its professional endeavors, TPG remains deeply committed to giving back to the community, sponsoring and supporting various organizations that benefit patients and caregivers. By participating in events such as the Donna Marathon, which supports breast cancer research, TPG embodies its ethos of gradual growth and collaboration to benefit more patients over time.